John Kelly

Targetome SA operates is a biotech company which develops affinity-based targeted therapies against unmet medical needs with initial focus on pancreatic cancer and liver metastases. The firm develops antibody-drug conjugates. The company was founded by Edwin de Pauw and Vincent Castronovo in 2010 and is headquartered in Liege, Belgium.

Targetome SA operates is a biotech company which develops affinity-based targeted therapies against unmet medical needs with initial focus on pancreatic cancer and liver metastases. The firm develops antibody-drug conjugates. The company was founded by Edwin de Pauw and Vincent Castronovo in 2010 and is headquartered in Liege, Belgium.

Targetome SA operates is a biotech company which develops affinity-based targeted therapies against unmet medical needs with initial focus on pancreatic cancer and liver metastases. The firm develops antibody-drug conjugates. The company was founded by Edwin de Pauw and Vincent Castronovo in 2010 and is headquartered in Liege, Belgium.

Targetome SA operates is a biotech company which develops affinity-based targeted therapies against unmet medical needs with initial focus on pancreatic cancer and liver metastases. The firm develops antibody-drug conjugates. The company was founded by Edwin de Pauw and Vincent Castronovo in 2010 and is headquartered in Liege, Belgium.

Targetome SA operates is a biotech company which develops affinity-based targeted therapies against unmet medical needs with initial focus on pancreatic cancer and liver metastases. The firm develops antibody-drug conjugates. The company was founded by Edwin de Pauw and Vincent Castronovo in 2010 and is headquartered in Liege, Belgium.